Brief Introduction

Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) was founded in Shenzhen on 2001, specializing in the research and development of novel small molecule drugs. Within house-built proprietary chemical genomics-based drug discovery and early evaluation platform as its core competitiveness, "integrated Chipscreen Biosciences has now become one of China's leading innovative drug enterprises, forming a modern biopharmaceutical group company in Shenzhen, as its headquarter, research and development center, and GMP production base, Chengdu, as a regional headquarter for research and development center and a large scale GMP production base for both drug substances and products, Beijing clinical research centerand Shanghai Commercial center. At present, the company has developed a number of original new drug product lines for oncology, metabolic diseases, and autoimmune diseases.

Company Overview

Full name Shenzhen Chipscreen Biosciences Co., Ltd.
Abbreviations Chipscreen Biosciences
Code 688321
Founded 2001-03-21
Listing 2019-08-12
Domicile Shenzhen
STAR Theme Biomedicine
CSRC Sector Manufacturing
Has weighted voting rights structure? No



  2020 2019 2018
Earnings Per Share 0.07 0.05 0.09
R&D expenditure as a % of operating revenue 50.94% 45.02% 55.85%
Operating Revenue 269,469,784.74 173,800,400.62 147,688,982.21
Net Income 31,045,971.89 19,421,886.44 31,164,799.98

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 269.47 173.80 147.69
Operating Costs 13.48 7.29 5.51
Operating Income 36.98 23.28 32.64
Pretax Income 36.17 20.73 32.17
Income Tax 5.12 1.31 1.00
Net Income 31.05 19.42 31.16

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Current Assets-Total 769.06 1072.23 233.47
Non-current Assets-Total 957.21 619.19 482.87
Total Assets 1726.27 1691.42 716.34
Current Liabilities-Total 146.89 137.31 81.53
Non-current Liabilities-Total 85.55 107.79 157.91
Total Liabilities 232.44 245.10 239.44
Stockholder's Equity
Share Capital 410.00 410.00 360.00
Retained Profits 77.30 37.98 -39.02
Total Owners' Equity 1493.83 1446.33 476.90

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating 93.62 -24.55 22.78
Net Cash Flows-Investing -108.69 -721.48 -13.33
Net Cash Flows-Financing -45.38 950.20 17.95

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
博奥生物集团有限公司 42.92 10.47%
LAV One (Hong Kong) Co., Limited 24.50 5.98%
深圳市海粤门生物科技开发有限公司 22.94 5.59%
LU XIANPING 22.19 5.41%
Vertex Technology Fund (III) Ltd 20.60 5.03%
深圳海德睿博投资有限公司 19.82 4.83%
深圳市海德康成投资合伙企业(有限合伙) 15.29 3.73%
深圳市永智资产管理有限公司-萍乡永智英华元丰投资合伙企业(有限合伙) 14.70 3.59%
深圳市海德睿远企业管理合伙企业(有限合伙) 12.53 3.06%
深圳市海德睿达企业管理合伙企业(有限合伙) 12.53 3.06%
31 Mar 2021

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.